非小细胞肺癌生物标志物在个体化治疗方面的研究进展

Progress in biomarkers of non-small cell lung cancer for individualized treatment

通过对非小细胞肺癌(NSCLC)生物标志物的监测,能指导临床有效诊断疾病,提高治疗效果,降低其他治疗方式产生的毒副作用,并能改善预后,预测疾病的复发和耐药性的产生。本文通过检索数据库,总结归纳了近年来新发现及常用于NSCLC预测疾病进程、预后及指导药物靶向治疗、放化疗的生物标志物,以期为指导NSCLC患者个体化治疗及疾病诊断、调整治疗方案提供依据和参考。

Biomarkers of non-small cell lung cancer（NSCLC）can facilitate an efficient diagnosis,improve therapeutic effects,reduce the side effects of other treatments,ameliorate prognosis and predict relapse of the disease and drug resistance. This paper summarized the biomarkers which were newly discovered and their functions in clinical practices in order to guide individualized treatment and help adjust treatment. The exploration of biomarkers of NSCLC will become a priority in future research.